TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A retrospective analysis of 359,595 adults with type 2 diabetes found lower estimated obesity-related cancer risk among GLP-1 receptor agonist users than among insulin or sulfonylurea users. Differences were clearest in patients with less severe diabetes, while comparisons with metformin, DPP-4 inhibitors and SGLT2 inhibitors showed no consistent difference. The study does not establish that any medication prevents or causes cancer.
A retrospective study of 359,595 adults with type 2 diabetes found that use of GLP-1 receptor agonists was associated with lower estimated risk of obesity-related cancers than use of insulin or sulfonylureas, with the clearest differences among people with less severe diabetes. The analysis, published November 5 in JAMA Network Open, found no significant overall difference against metformin, DPP-4 inhibitors or SGLT2 inhibitors, and cannot show that the drugs prevent cancer.
Researchers compared people starting GLP-1 receptor agonists with patients starting other diabetes medicines, using electronic health record data from PCORnet. The adults were treated at a single center between January 2010 and July 2025. The team conducted five active-comparator analyses and grouped patients by diabetes severity, based on complications recorded before treatment, including cardiovascular disease and stages of diabetic kidney disease.
At three years, the estimated risk of obesity-related cancers was 2.01% among GLP-1 users and 3.26% among insulin users. In the comparison with sulfonylureas, the corresponding estimates were 2.85% and 3.98%. These are observational estimates, not proof that the drug choice caused the difference. The study reported statistically significant comparisons against insulin and sulfonylureas in the overall analysis and in the low-severity group.
The pattern generally remained at five years, with risk estimates favoring GLP-1 drugs over insulin and sulfonylureas in nearly all severity categories. By contrast, cancer risk did not differ significantly from that among people who started metformin, a DPP-4 inhibitor or an SGLT2 inhibitor. For patients with moderate or high diabetes severity, SGLT2 inhibitor treatment had more favorable estimates during the first three years, according to the report.
Why Drug Comparisons Change the Picture
The findings matter because diabetes medicines are prescribed to patients with different health histories and at different stages of illness. A comparison that shows lower cancer incidence for GLP-1 users than for insulin users does not mean the same association applies against every alternative. In this study, the apparent difference depended on both the medication used as a comparator and the patient’s baseline diabetes severity.
That distinction is relevant to patients weighing treatment options and to clinicians interpreting emerging research about cancer outcomes. The results do not support switching an otherwise suitable medicine solely to lower cancer risk. As study author Jesús Gibran Hernández-Pérez told MedPage Today, treatment decisions should continue to reflect established metabolic, cardiovascular and kidney benefits, as well as individual needs.
Products Worth Considering
Sinimaka 8-Pack Polycarbonate Greenhouse Panels, 8 x 4 ft, 6mm Twin-Wall, UV-Coated Translucent
Orbit B-hyve XR 16-Zone Indoor/Outdoor Smart Sprinkler Timer
Greenworks 40V 16-inch Push Lawn Mower with 4.0 Ah Battery and Charger
As an affiliate, we earn on qualifying purchases.
How Researchers Compared Diabetes Treatments
Obesity and diabetes are both associated with increased cancer risk, and earlier observational studies have reported lower rates of some obesity-related cancers among GLP-1 receptor agonist users. The new analysis extends that research by comparing GLP-1 treatment with several other diabetes drug classes rather than treating all non-GLP-1 therapies as one group.
The researchers described their approach as a way to identify settings in which associations were most apparent, not to prove that one treatment is superior for cancer outcomes. They assessed outcomes at three and five years and accounted for baseline severity categories. Because the study is retrospective and based on clinical records, treatment selection and differences in patients’ health could still shape the results, even after statistical adjustment.
“When we talk about GLP-1 receptor agonists and cancer risk, we need to ask, ‘compared with which medication, and in which patients.'”
— Jesús Gibran Hernández-Pérez, PhD, of UT Southwestern Medical Center, speaking to MedPage Today
What the Observational Data Cannot Show
The analysis cannot establish whether GLP-1 receptor agonists directly affect cancer risk. People prescribed insulin, sulfonylureas and other medicines may differ in illness duration, complications, treatment history or other factors that also influence cancer risk. The researchers adjusted for measured differences, but electronic health record analyses cannot account fully for every potential source of bias.
The report also does not establish that the observed differences apply to every patient or to cancers beyond the study’s obesity-related cancer outcomes. In the most severe diabetes group, the estimated risk was higher for GLP-1 users than sulfonylurea users in one comparison, but the difference was not statistically significant. That estimate should not be treated as evidence of increased risk.
Treatment Choices and Further Research
The study does not announce a treatment change or a new clinical recommendation. For now, its authors advise against choosing or changing diabetes medication solely on the basis of cancer risk findings from this analysis. Patients should discuss treatment decisions with a qualified health professional, considering their full medical history and the known benefits and risks of available therapies.
Further research will be needed to test whether these associations persist in other patient populations and study designs, and to clarify how diabetes severity and treatment history relate to cancer outcomes. Until then, the central finding is comparative and observational: GLP-1 use was associated with lower estimated risk than insulin or sulfonylureas, particularly among patients with lower-severity diabetes, but not consistently compared with other drug classes.
Key Questions
Did the study show that GLP-1 drugs prevent cancer?
No. It found associations in retrospective data and did not establish that GLP-1 receptor agonists cause a reduction in cancer risk.
Which medicines were compared with GLP-1 receptor agonists?
The researchers compared GLP-1 drugs with insulin, sulfonylureas, metformin, DPP-4 inhibitors and SGLT2 inhibitors. Significant overall differences were reported against insulin and sulfonylureas, not the other classes.
How did diabetes severity affect the findings?
The differences favoring GLP-1 treatment over insulin or sulfonylureas were most apparent among patients with low-severity diabetes. Comparisons were less consistent in groups with more severe disease.
Should patients change medication because of these results?
The study author said patients should not change an otherwise appropriate treatment solely to reduce cancer risk based on these findings. Treatment decisions should be made with a qualified health professional, taking individual needs and established medication benefits into account.
Source: medpagetoday.com
